Dudediligence.

Oruka Therapeutics, Inc

ORKANASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

61.1M

on 2026-06-30, from 14.5M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

20M40M60MMar2024JunSepDecMar2025JunSepDecMar2026Jun$72.50

Newest

$500.0M

S-3 of 2026-08-21. 1 prospectus supplement filed under it since. S-3 ↗

$500.0M

TD Securities (USA), agreement of 2025-10-03. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-10 is not read yet.

Cash

34.6 quarters

$873.6M on 2026-06-30 ÷ $25.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-04-28Public offering9,660,000$72.50$700.4M424B5 ↗